Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Steven Nelson

Family Medicine Stockton, CA Medical Doctor

NPI 1558327908 CMS profile 342844

2505 W Hammer Ln, Stockton, CA 95209

Open in the dashboard

General payments

$1,627

92 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Steven Nelson of Stockton, CA is reported in the CMS Open Payments database as having received $1,627 across 92 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 76th percentile of Family Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $19 1
2023 General $56 3
2022 General $138 3
2021 General $17 1
2020 General $488 32
2019 General $908 52

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Steven Nelson
  • Family Medicine median
  • Middle half of Family Medicine
  • National median

In program year 2025, general payments to Steven Nelson were reported at $0. Among 56,786 Family Medicine profiles paid that year, the median was $155 and the middle half received between $45 and $549.

Show as a table
Year Steven Nelson Family Medicine median Middle half National median
2019 $908 $150 $41–$543 $163
2020 $488 $120 $32–$415 $114
2021 $17 $137 $35–$551 $132
2022 $138 $137 $37–$512 $149
2023 $56 $149 $42–$545 $160
2024 $19 $156 $44–$560 $164
2025 $0 $155 $45–$549 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Novo Nordisk Inc $549 31 payments
  2. Boehringer Ingelheim Pharmaceuticals, Inc. $277 15 payments
  3. Lilly USA, LLC $133 9 payments
  4. Teva Pharmaceuticals USA, Inc. $119 1 payment
  5. Merck Sharp & Dohme Corporation $101 6 payments
  6. Pfizer Inc. $92 6 payments
  7. AstraZeneca Pharmaceuticals LP $62 5 payments
  8. E.R. Squibb & Sons, L.L.C. $58 4 payments
  9. Antares Pharma, Inc. $53 3 payments
  10. Allergan Inc. $51 3 payments
  11. Other $132 9 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $1,627 92 payments
Products named General payments · program years 2019–2024
  1. Ozempic $310 20 payments
  2. RYBELSUS $211 15 payments
  3. JARDIANCE $191 10 payments
  4. SPIRIVA RESPIMAT $170 9 payments
  5. Saxenda $120 2 payments
  6. CINQAIR $119 1 payment
  7. EMGALITY $82 5 payments
  8. ELIQUIS $58 4 payments
  9. STEGLATRO $54 3 payments
  10. JANUVIA $54 3 payments
  11. Other $981 66 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 140 drugs

Part D claims

7,730

Median for Family Practice: 1,826

Drug cost

$509,973

Median for Family Practice: $120,094

Branded share of claims

26.1%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 140 $154,088
Eliquis Apixaban Brand 86 $82,346
Jardiance Empagliflozin Brand 76 $78,410
Mounjaro Tirzepatide Brand 20 $19,373
Januvia Sitagliptin Phosphate Brand 25 $18,771
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 433 $11,024
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 14 $9,822
Tresiba Flextouch U-100 Insulin Degludec Brand 11 $9,728
Breo Ellipta Fluticasone/Vilanterol Brand 17 $6,859
Firvanq Vancomycin Hcl Brand 26 $6,608

The 10 drugs with the highest cost, of 140 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 36 billing codes

Paid by Medicare

$105,994

Of which drugs: $33,403

Medicare patients

342

Average age 75

Services billed

2,765

199 women, 143 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 40%
Diabetes 31%
Ischemic heart disease 23%
Chronic kidney disease 17%
Atrial fibrillation 15%
Osteoporosis 14%
COPD 13%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 13 1,440 $29,403
Vaccine for influenza for injection into muscle 90653 Office 15 15 $1,227

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

92 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Family Medicine in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record